1. Home
  2. ATYR

as of 03-06-2026 3:58pm EST

$0.83
$0.07
-8.25%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Founded: 2005 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 69.2M IPO Year: N/A
Target Price: $4.20 AVG Volume (30 days): 1.5M
Analyst Decision: Hold Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.64 - $7.29 Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -58.22% Revenue Growth (next year): 18728.62%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered ATYR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 71.67%
71.67%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest aTyr Pharma Inc. News

ATYR Breaking Stock News: Dive into ATYR Ticker-Specific Updates for Smart Investing

All ATYR News

Share on Social Networks: